vTv Therapeutics (VTVT) Projected to Release Earnings on Thursday

vTv Therapeutics (NASDAQ:VTVT) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($1.07) per share and revenue of $0.33 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Friday, November 6, 2026 at 4:00 PM ET.

vTv Therapeutics (NASDAQ:VTVT) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.08). On average, analysts expect vTv Therapeutics to post ($2.35) EPS for the current fiscal year and ($4.53) EPS for the next fiscal year.

vTv Therapeutics Price Performance

VTVT opened at $25.72 on Thursday. The business has a 50 day moving average price of $30.57 and a two-hundred day moving average price of $33.66. The company has a market cap of $101.34 million, a PE ratio of -24.26 and a beta of 0.21. vTv Therapeutics has a 52 week low of $19.80 and a 52 week high of $44.00.

Analyst Upgrades and Downgrades

VTVT has been the topic of several analyst reports. Wall Street Zen downgraded vTv Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, October 24th. HC Wainwright cut their price target on vTv Therapeutics from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, August 6th. Zacks Research raised vTv Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, September 7th. Weiss Ratings lowered shares of vTv Therapeutics from a “sell (d+)” rating to a “sell (d-)” rating in a research report on Tuesday, August 11th. Finally, BTIG Research reissued a “buy” rating and issued a $57.00 price objective on shares of vTv Therapeutics in a research note on Wednesday, October 14th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $55.83.

vTv Therapeutics Company Profile

vTv Therapeutics Inc (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on developing orally administered therapies for metabolic and neurological diseases. The company uses small-molecule drug discovery and development programs to address conditions with significant unmet medical needs.

Its lead product candidate is TTP399, an oral, liver-selective glucokinase activator being developed as an adjunctive treatment for people with type 1 diabetes. The company has also developed other investigational therapies, including compounds targeting type 2 diabetes, obesity and Alzheimer’s disease.